Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

Documentation of side effects

Outcome Time Frame:

3 years

Safety Issue:

Yes

Principal Investigator

Martin Fassnacht, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Wuerzburg

Authority:

Germany: Ethics Commission

Study ID:

Wue-ACC-Mitotane

NCT ID:

NCT00568139

Start Date:

January 2008

Completion Date:

December 2013

Related Keywords:

• Adrenocortical Carcinoma
• adrenal cancer
• mitotane (Lysodren)
• adverse events
• Carcinoma
• Adrenocortical Carcinoma

Name	Location